Research Topics
| Barry KahanSummaryAffiliation: Baylor College of Medicine Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatmentBarry Kahan
The University of Texas Medical School at Houston, Texas Heart Institute, St Luke s Episcopal Hospital, Department of Surgery, Houston 77030, USA
Expert Opin Drug Saf 10:727-49. 2011....- Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I studyBarry D Kahan
Department of Surgery, University of Texas Health Science Center at Houston, Houston, TX, USA
Transplantation 76:1079-84. 2003..This study examined the safety, pharmacodynamics, and pharmacokinetics of multiple doses of FTY720 in stable renal transplant patients... - Therapeutic drug monitoring of cyclosporine: 20 years of progressB D Kahan
University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA
Transplant Proc 36:378S-391S. 2004.... - FTY720: from bench to bedsideB D Kahan
University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA
Transplant Proc 36:531S-543S. 2004.... - Sirolimus-based immunosuppression: present state of the artBarry D Kahan
Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA
J Nephrol 17:S32-9. 2004.... - Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejectionBarry D Kahan
Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA
Transplantation 78:858-63. 2004.... - Forty years of publication of transplantation proceedings--the second decade: the cyclosporine revolutionBarry D Kahan
Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston Medical School, Houston, Texas 77030, USA
Transplant Proc 41:1423-37. 2009..Transplantation had now achieved its rightful place in the clinical armamentarium... - Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipientsBarry D Kahan
The University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA
Transplantation 80:749-58. 2005..One approach to addressing this problem is identifying agents that display antineoplastic properties concomitant with their immunosuppressive effects... - Use of sirolimus to facilitate steroid withdrawal from a cyclosporine regimenB D Kahan
Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, Texas 77030, USA
Transplant Proc 38:2842-6. 2006..Because sirolimus blocks one of the sites affected by steroids, we sought to examine whether substituting this drug mitigated these toxicities... - Fifty years in the vineyard of transplantation: looking backB D Kahan
Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston Medical School, Houston, Texas 77030, USA
Transplant Proc 43:2853-9. 2011..These experiences have afforded insights into future avenues for preclinical exploration and therapeutic drug development... - The ruby anniversary: forty years of publication of Transplantation Proceedings - the first decade: the flowering of immunology and immunogeneticsB D Kahan
University of Texas Medical School at Houston, Department of Surgery, Division of Immunology and Organ Transplantation, Houston, Texas 77030, USA
Transplant Proc 41:5-10. 2009..Initial clinical successes revealed technical accomplishments that warranted broader application of this technology as described in the second decade of the Proceedings-the advent of cyclosporine... - Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimusB D Kahan
Division of Immunology and Organ Transplantation, The University of Texas Medical School, Houston, TX 77030, USA
Clin Nephrol 73:344-53. 2010..We sought to examine the improvement in renal function with preserved immunosuppression consequent to reducing de novo cyclosporine (CsA) doses combined with sirolimus and induction antibody treatment... - Frontiers in immunosuppressionB D Kahan
The University of Texas Medical School at Houston, Houston, TX, USA
Transplant Proc 43:822-5. 2011..Preliminary work in animal models supports these avenues for future drug development... - Individuality: the barrier to optimal immunosuppressionBarry D Kahan
Division of Immunology and Organ Transplantation, Department of Surgery, University of Texas Medical School at Houston, Suite 6 240, 6431 Fannin, Houston, Texas 77030, USA
Nat Rev Immunol 3:831-8. 2003..Approaches presently under investigation aim to alter cell trafficking, or selectively deviate the maturation of antigen-presenting cells or inhibit lymphocyte-activation cascades - events that are crucial to rejection responses... - RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejectionB D Kahan
Division of Immunology and Organ Transplantation, The University of Texas Medical School at Houston, 6431 Fannin St, Suite 6 240, Houston, TX 77030, USA
Transplantation 71:1400-6. 2001.... - Sirolimus: a comprehensive reviewB D Kahan
Division of Immunology and Organ Transplantation, University of Texas Houston, 6431 Fannin, Suite 6 240, Houston, TX 77030, USA
Expert Opin Pharmacother 2:1903-17. 2001.... - Therapeutic drug monitoring of immunosuppressant drugs in clinical practiceBarry D Kahan
Division of Immunology and Organ Transplantation, University of Texas Health Science Center at Houston Medical School, 77030, USA
Clin Ther 24:330-50; discussion 329. 2002..Therapeutic drug monitoring (TDM) is essential to maintain the efficacy of many immunosuppressant drugs while minimizing their toxicity. TDM has become more refined with the development of new monitoring techniques and more specific assays... - Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimusBarry D Kahan
University of Texas Medical School at Houston, Department of Surgery, Division of Immunology and Organ Transplantation, Houston, Texas 77030, USA
Ther Drug Monit 24:47-52. 2002..These two new agents are likely to usher in a new era of transplant therapy... - Current immunosuppressant regimens: considerations for critical careB D Kahan
Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA
Curr Opin Crit Care 7:242-50. 2001..Among them, only FTY720 is undergoing large-scale human clinical trials. With its unique mechanism of action and synergistic interactions with cyclosporine and sirolimus, it may provide the foundation for a new era in immunosuppression... - Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantationRichard J Knight
Department of Surgery, The Methodist Hospital, Houston, TX 77030, USA
Transplantation 89:727-32. 2010..A prednisone and calcineurin inhibitor (CNI)-free protocol was compared with a sirolimus, cyclosporine A (CsA), and prednisone-based immunosuppressive regimen for simultaneous pancreas-kidney transplantation (SPK)... - Repeat renal allografts treated with sirolimus, cyclosporine, anti-thymocyte globulin induction and continuous steroids achieve similar immunosuppressive efficacy as primary transplantsVirgilio G Petero
Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston Medical School, Houston, TX 77030, USA
Clin Transplant 24:243-51. 2010..We sought to examine repeat versus primary renal transplantations using sirolimus-based regimens... - Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipientsRobert M Langer
The University of Texas Medical School at Houston, Department of Surgery, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA
Transplantation 74:804-8. 2002..4% (29/135) group III patients (P <0.001). CONCLUSIONS: Addition of sirolimus to a CsA-Pred regimen resulted in both a higher incidence and a requirement for more aggressive treatment of perinephric fluid collections and lymphoceles... - Thymoglobulin, sirolimus, and reduced-dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantationRichard J Knight
Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston, Texas 77030, USA
Transplantation 75:1301-6. 2003..We believe that careful monitoring of sirolimus and cyclosporine levels was critical to success of this protocol... - BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomesCarlos A Benavides
Division of Immunology and Organ Transplantation, Department of Surgery, University of Texas Medical School at Houston, Houston, TX, USA
Transplantation 84:83-8. 2007.... - Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokinesRobert Langer
Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School Houston, 6431 Fannin, Suite 6 240, Houston, TX 77030, USA
J Am Soc Nephrol 15:2893-901. 2004..Thus, BIMO blocks allograft rejection by reduction of intragraft expression of cytokines and chemokines... - [Improved outcome with sirolimus-cyclosporine regimen in high-risk renal transplant recipients]Hemangshu Podder
Division of Immunology and Organ Transplantation, The University of Texas Medical School at Houston, Houston, Texas 77030, USA
Orv Hetil 146:1641-6. 2005..Therefore, a good combination will allow not only to reduce individual immunosuppressive drug induced toxicities but will also allow to achieve better graft and patient survival... - Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year resultsGeorge W Burke
Department of Surgery, University of Miami, Miami, Florida 33136, USA
Transplantation 77:1269-75. 2004..Induction agents included T-cell-depleting and interleukin-2 receptor antibodies... - Impact of reduced nephron mass on cyclosporine- and/or sirolimus-induced nephrotoxicityIda Fernandes
Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School, Houston, TX, USA
Transplantation 88:1323-31. 2009..We evaluated the impact of reduced nephron mass on nephrotoxicity by cyclosporine A (CsA) and/or sirolimus (SRL)... - Allograft rejection requires STAT5a/b-regulated antiapoptotic activity in T cells but not B cellsYe Zhang
Division of Immunology and Organ Transplantation, Department of Surgery, University of Texas Medical School, Houston, TX 77030, USA
J Immunol 176:128-37. 2006..Thus, activated STAT5a/b-/- T cells produce cytokines prior to entering apoptosis, thereby promoting differentiation of B cells yielding donor-specific IgM and IgG Ab that mediate allograft rejection... - Selection of lowly immunogenic and highly tolerogenic donor and recipient allochimeric class I major histocompatibility complex proteinsJohn Perez
Department of Surgery, The University of Texas Medical School at Houston, Houston, Texas 77030, USA
Transplantation 76:1201-7. 2003..CONCLUSIONS: The poorly immunogenic alpha1h52-90n-RT1.Ac allochimeric protein induces tolerance by selective activation of regulatory Th2 cells... - FTY720: A new kid on the block for transplant immunosuppressionFazil Tuncay Aki
The University of Texas Medical School at Houston, Department of Surgery, Suite 6.240, 6431 Fannin, Houston, TX 77030, USA
Expert Opin Biol Ther 3:665-81. 2003..Clearly, structural analogues, as well as other agents that alter the balance of chemokines or affect cellular adhesion to activated endothelium, will represent important components of future regimens... - Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosisShih-Chieh J Chueh
Division of Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, TX, USA
Transplantation 76:375-82. 2003..CONCLUSION: The dyslipidemia associated with sirolimus therapy, albeit persistent, does not seem to represent a major risk factor for the early emergence of cardiovascular complications... - Effect of sirolimus treatment on gene expression in renal transplant patientsKasey Vickers
Department of Medicine, Baylor College of Medicine, Houston, TX, USA
World J Surg 31:644-53. 2007..The rapamycin signaling pathway [mammalian target of rapamycin (mTOR)] has been implicated in transcriptional regulation... - Interventional radiologic management of renal transplant dysfunction: indications, limitations, and technical considerationsKatsuhiro Kobayashi
Department of Diagnostic and Interventional Imaging, University of Texas Medical School at Houston, 6431 Fannin St, Houston, TX 77030, USA
Radiographics 27:1109-30. 2007..In addition, familiarity with the indications for and limitations of these techniques as well as collaboration between the radiologist and the transplantation surgeon are vital for maximizing the chances of renal allograft survival... - Risk factors for impaired wound healing in sirolimus-treated renal transplant recipientsRichard J Knight
Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston, Houston, TX, USA
Clin Transplant 21:460-5. 2007..As sirolimus has been implicated in impaired wound healing, the aim of this study was to evaluate risk factors for wound complications after renal transplantation in patients treated with this drug de novo... - De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combinationRobert M Langer
The University of Texas Medical School at Houston, Department of Surgery, Division of Immunology and Organ Transplantation, Suite 6.240, 6431 Fannin, Houston, TX 77030, USA
Transplantation 73:756-60. 2002..CONCLUSION: This initial experience suggests that a time-limited and reversible de novo HUS syndrome may be less frequent and milder among renal transplant recipients treated with SRL-based immunosuppression... - Pancreas transplantation utilizing thymoglobulin, sirolimus, and cyclosporineRichard J Knight
Division of Immunology and Organ Transplantation, The University of Texas Health Science Center, Houston, TX 77030, USA
Transplantation 81:1101-5. 2006..This study aims to determine the impact of thymoglobulin-sirolimus-cyclosporine immunosuppression on the alloimune response of pancreas-kidney transplant recipients... - Losing the kingdom: the case against commercial organ donationBarry D Kahan
Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas, Medical School, Houston, TX 77030, USA
Nat Clin Pract Urol 4:290-1. 2007 - Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patientsJoel D Morrisett
The Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
J Lipid Res 43:1170-80. 2002.... - Allochimeric class I MHC protein-induced tolerance by partial TCR engagement requires activation of both CTL4- and common gamma-chain-dependent cytokine signalsStanislaw M Stepkowski
Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, Texas 77030, USA
Transplantation 73:1227-35. 2002..The various toxicities associated with the general immune suppression resulting from current clinical immunosuppressive therapies continue to plague transplant recipients as well as jeopardize allograft survival... - The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft functionRichard J Knight
Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Transplantation 78:904-10. 2004..The present study reviews our experience with the substitution of thymoglobulin for basiliximab as induction therapy for recipients at increased risk for early acute rejection episodes... - The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicitiesStanislaw M Stepkowski
Division of Immunology and Organ Transplantation, Department of Surgery, University of Texas Medical School at Houston, Houston, TX 77030, USA
J Immunol 175:4236-46. 2005..In contrast to CsA, NC1153 was not metabolized by cytochrome P450 3A4. Thus, NC1153 prolongs allograft survival without several toxic effects associated with current immunosuppressive drugs... - Long-term outcomes of single paediatric vs. ideal adult renal allograft transplants in adult recipientsZsolt Csapo
Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Clin Transplant 20:423-6. 2006..CONCLUSION: Transplantation of single paediatric donor kidneys into low BMI adult recipients provided equivalent outcomes to those of grafts from adult donors between the ages of 18 and 45 yr... - Sirolimus: a current perspectiveYarkin K Yakupoglu
The University of Texas Medical School at Houston, Department of Surgery, Division of Immunology and Organ Transplantation, 6431 Fannin, Suite 6.240, Houston, TX 77030, USA
Exp Clin Transplant 1:8-18. 2003..Therefore, sirolimus proffers a potent and unique platform for new immunosuppressive strategies in organ transplantation... - Janus kinase 3: a novel target for selective transplant immunosupressionHemangshu Podder
The University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, 6431 Fannin Street, Suite 6 240, Houston, TX 77030, USA
Expert Opin Ther Targets 8:613-29. 2004.... - 100 years ago: Ullmann's pioneering operation--autotransplantation of the kidneyR M Langer
Division of Immunology and Organ Transplantation, University of TexasMedical School at Houston, 6431 Fannin, Houston, TX 77030, USA
Transplant Proc 34:429-33. 2002 - Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantationJohn M Kovarik
Novartis Pharmaceuticals, Basel, Switzerland 4002
Am J Transplant 3:606-13. 2003..Weight-adjusted dosing (mg/kg) does not appear warranted. Black patients may have lower bioavailability and/or higher clearance of everolimus compared with white patients... - Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppressionJames T Burke
Wyeth Research, Paris, France
Transpl Int 21:434-40. 2008..001). The accuracy of the three eGFR equations was affected by mGFR range but not by immunosuppressive regimens utilizing SRL, SRL-CNI or CNI-based therapy... - Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycinStanislaw M Stepkowski
Department of Surgery Division of Immunology and Organ Transplantation and University of Texas Medical School at Houston, USA
Blood 99:680-9. 2002..It is concluded that inhibition of signal 3 alone by targeting Jak3 in combination with a signal 1 inhibitor provides a unique strategy to achieve potent immunosuppression... - [Lymphocele and kidney transplantation]Robert Langer
Semmelweis Egyetem, Általános Orvostudományi Kar, Transzplantációs és Sebészeti Klinika, Budapest
Orv Hetil 148:1475-80. 2007..Aim: From the point of view of the lymphocele a comparison was made for the risks and benefits of the conventional and a newer immunosuppressive combination... - Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipientsRobert M Langer
Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary
Transplantation 76:318-23. 2003..CONCLUSION: Addition of sirolimus to a CsA+Pred regimen does not increase the incidence of postoperative thrombotic events among renal transplant recipients... - Toward calcineurin antagonist minimizationBarry D Kahan
Transplantation 77:162; author reply 162-3. 2004 - FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantationHelio Tedesco-Silva
Hospital do Rim e Hipertensao, Borges Lagoa 960, Sao Paulo, SP 04038 002, Brazil
Transplantation 77:1826-33. 2004..Its effect relates to the modulation of lymphocytes trafficking from blood and peripheral tissues to lymph nodes. This is the first study to evaluate the efficacy and safety of FTY720 in de novo renal transplantation... - Metabolic interaction between cyclosporine and sirolimusShuang Bai
Pharmaceutics Division, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712-0126, USA
Transplantation 77:1507-12. 2004..Changes in the individual activities of CYP3A1/2 and Pgp may contribute to an interaction between CsA and SRL resulting in unanticipated effects during chronic therapy... - Clinical application of sirolimus in renal transplantation: an updateShih-Chieh J Chueh
Department of Urology, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
Transpl Int 18:261-77. 2005.... - FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantationHelio Tedesco-Silva
Hospital do Rim e Hipertensao, Sao Paulo 04038 002, Brazil
Transplantation 79:1553-60. 2005..Its effect relates to the modulation of lymphocytes trafficking from blood and peripheral tissues to lymph nodes. This is the first study to evaluate the efficacy and safety of FTY720 in de novo renal transplantation... - Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic rangeJohn M Kovarik
Novartis Pharmaceuticals, Basel, Switzerland
Transplantation 73:920-5. 2002..An upper therapeutic concentration limit is likely more than 15 ng/ml but a precise value could not be derived from these data... - Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignanciesH Myron Kauffman
Research Department, United Network for Organ Sharing, Richmond, VA, USA
Transplantation 80:883-9. 2005..In animal models, calcineurin inhibitors have a positive growth effect, whereas target-of-rapamycin (TOR) inhibitors have a negative growth effect on malignant cells... - A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejectionTimothy H Mathew
Clinical Pharmacology Department, A3042, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA
J Clin Pharmacol 46:76-87. 2006..The tablet and solution formulations of sirolimus demonstrated therapeutic equivalence... - Randomized controlled trial of FTY720 versus MMF in de novo renal transplantationHelio Tedesco-Silva
Setor de Transplante Renal, Hospital do Rim Hipertensão UNIFESP, Rua Borges, Lagoa, 960 11o andar, Sao Paulo, SP, Brazil
Transplantation 82:1689-97. 2006..Phase II trials of FTY720, a novel immunomodulator, have shown promise in preventing rejection with both standard and reduced cyclosporine exposure. This study was designed to confirm those findings... - Review: metabolism of immunosuppressant drugsPatrick Kelly
Novartis Pharmaceuticals Corp, Medical Affairs/Transplantation, Summit, NJ 07901, USA
Curr Drug Metab 3:275-87. 2002..Because of the critical-dose nature of most of the recent generation of immunosuppressive agents, therapeutic drug monitoring is becoming increasingly important in the selection of doses and treatment regimens... - Fokko Johannes van der Woude, 1953-2006Barry D Kahan
Transplant Proc 39:321-4. 2007
Research Grants
- PHARMACOLOGY OF CYCLOSPORINE BASED IMMUNOSUPPRESSIONBarry Kahan; Fiscal Year: 2000..In aggregate studies seek to describe quantitative the potential benefits and/or risks of CsA-based drug combinations in order to select agents suitable for use in clinical trials. ..
- PHARMACOLOGY OF CYCLOSPORINE-BASED IMMUNOSUPPRESSIONBarry Kahan; Fiscal Year: 1993....
- CYCLOSPORINE PHARMACOLOGY IN CLINICAL TRANSPLANTATIONBarry Kahan; Fiscal Year: 1991..The combined pharmacokinetic and pharmacodynamic approach will provide a foundation to design, monitor, evaluate and enhance with efficacy of CsA dosing regimens for renal, cardiac, hepatic and pancreatic transplant recipients...
- PHARMACOLOGY OF CYCLOSPORINE BASED IMMUNOSUPPRESSIONBarry Kahan; Fiscal Year: 2004....